Vor Biopharma is an immuno-oncology company developing novel therapies with broad potential for treating cancer. Vor is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells. Cell surface-targeted immunotherapies, such as bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) T cells, generally target both cancer and normal cells, causing substantial toxicities and limiting their potential. Vor is taking a fundamentally novel approach to targeting cancer selectively by developing hematopoietic stem cells (HSCs) that have been engineered to be protected from specific targeted immunotherapies. These HSCs are designed to generate healthy, functional cells that are also protected from depletion by cancer-targeted therapies.
Vor’s platform is broad and can potentially be used to vastly improve the therapeutic window of several CAR-modified cells (such as CAR T cells, CAR NK cells, and others), expanding the reach of CAR-modified cells beyond B-cell malignancies to other myeloid leukemias, such as acute myeloid leukemia, as well as enhancing the effectiveness of other targeted immunotherapies such as antibody-drug conjugates or conventional antibodies targeted against leukemias. When combined with targeted therapies, this technology could potentially enable transformative outcomes in patients with otherwise grim prognoses.
This technology platform is covered by broad intellectual property exclusively licensed from Columbia University based on the pioneering work of Dr. Siddhartha Mukherjee, as well as Vor’s own intellectual property. Co-founded by PureTech Health (LSE: PRTC), Vor is working with some of the world’s leading oncologists and immunologists to develop a pipeline of potentially life-altering immunotherapies that extend beyond what is possible with current treatment.
Robert Ang, MD, MBA
Chief Executive Officer
Dr. Ang brings experience as a senior biotech executive and formerly a physician, venture capitalist and strategy consultant. Prior to Vor, Dr. Ang was Chief Business Officer at Neon Therapeutics, part of the early team establishing the company prior to its Series A investment through IPO. …
Bharatt chowrira, J.D., Ph.D.
Board of Directors
Bharatt Chowrira, JD, PhD, has been the President and Chief of Business and Strategy at PureTech Health since March 2017. Prior to joining PureTech Health, Dr. Chowrira was the President of Synlogic ...
bill lundberg, m.d.
board of directors
Dr. Bill Lundberg is a medical oncologist with more than 15 years of experience managing and leading biotechnology research and development. Most recently, Dr. Lundberg served as Chief Scientific Officer at CRISPR Therapeutics, establishing the company in Cambridge, Mass. …
Kush Parmar, M.D., Ph.D.
Executive Chairman, Board of Directors
Kush M Parmar, M.D., Ph.D., is a managing partner at 5AM Ventures. Dr. Parmar serves as a director on the Boards of Akouos, Arvinas, Entrada, Homology, and Rally Bio. He previously served as acting VP of strategy and corporate development at Novira (acquired by J&J) and served as Board Member or Observer for Achaogen, Audentes, Envoy (acquired by Takeda), and scPharmaceuticals ...
Josh Resnick, M.d.
Board of directors
Josh Resnick, M.D., is a managing director at RA Capital Management. Dr. Resnick’s primary responsibility at RA Capital is to lead early-stage private investments in and oversee the creation of new companies developing drugs, medical devices, diagnostics and research tools …
Parties interested in the roles below can send their resume and expressions of interest to firstname.lastname@example.org.
July 22, 2019: The Promise and Price of Cellular Therapies
Humbert O, Laszlo GS, Sichel S, Ironside C, Haworth KG, Bates OM, Beddoe ME, Carrillo PR, Kiem HP, Walter RB. Engineering resistance to CD-33 targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2. Leukemia. 2019 Mar; 33(3):762-808